OR WAIT 15 SECS
Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.
What the Indian government is doing to make its biotech sector as strong as its IT sector.
In most countries, commercial biopharma depends to some extent on taxpayer-sponsored infrastructure and incentives in the form of state-supported universities and research facilities that supply researchers and are centers of innovation. The same is certainly true for Indian biopharma, although, as noted in the recent report, Advances in Biopharmaceutical Technology in India, the Indian government's helping hand goes further than most.
Eric S. Langer
Almost all biopharmaceutical companies in India have had some form of government assistance in recent years such as public loan assistance enjoyed by many small biotech companies and Biocon's government-sanctioned Special Economic Zone (SEZ) in Bangalore, which will confer huge tax breaks on the company through 2015.1
India has never taken a laissez faire approach to its economy. This attitude is a legacy of the anti-colonial movement and the polarizing influence of the Cold War, in which socialism was seen as the most viable option to exploitative Western capitalism. The Indian National Congress, the party that dominated Indian politics for decades after independence, was essentially a socialist party. Even now, two of the other five national parties describe themselves as communist, and Indian economic policies continue to be organized according to old-fashioned, Russian-style five-year plans.
After the mid-1980s' decline of the Soviet empire, the West enjoyed an economic boom, and India's export markets expanded rapidly. The country began to outgrow its anti-Western sentiments, focusing instead on becoming a respected and powerful participant in the global economy.
At the time, the successes of American companies like Genentech and the advent of technologies like the polymerase chain reaction (PCR) were fostering the biotechnology revolution. India, therefore, decided to make biotechnology one of its priorities for industrial development, and in 1986, the Department of Biotechnology (DBT) was formed under the Ministry for Science and Technology.
Because product patents were not legal in India from 1972 until 2005, India's pharmaceutical industry based itself on reverse-engineering Western drugs and patenting new manufacturing processes. Although the pharmaceutical industry developed, biotechnology was still considered new and difficult, and Indian drug makers focused on synthetic chemistry rather than biological processes. By 2005, when product patents became legal again under the Patents (Amendment) Act, India was producing far more qualified graduates in chemistry than in biology.2 Moreover, most Indian biology graduates were doing their postdoctoral work in the West and ultimately emigrating there.3
The relative scarcity of qualified Indian graduates in biotech-related disciplines is now seen as a major limiting factor in the development of India's biotech industry. The DBT is trying to remedy the situation with initiatives that include:4
The DBT is also funding several programs to help push innovations out of academic laboratories and into production. These include:4
The Indian tax system is complex and evolving, but currently the local biopharmaceutical industry enjoys a host of actual and potential tax breaks. Among these are:6
In 2006, India's legislature passed the SEZ Act to promote both local and foreign investment, boost the influx of know-how from the West, and foster India's export sector. In principle, any company or group of companies may set up a SEZ on its own. The DBT is helping to finance the establishment of several biotechnology parks with SEZ status before 2010.
The benefits of SEZ status include:8
Public funding for biopharma-related research in India comes from a variety of sources. The DBT is one of the largest contributors, and others include:8
Biopharmaceutical industry suppliers also recognize that government support provides a level of stability, which leads to increased local investments. "The Indian government has encouraged an open-door policy with industry leaders," said Vinay Joban, general manager at Pall Life Sciences, Pall India. "The government has created excise-free zones to encourage pharmaceutical and biotechnology growth, and Pall and others are establishing new facilities and expanding existing facilities to meet international regulatory cGMP guidelines."
In the recent years, India's state governments, much like those in the US, have been competing for biopharmaceutical business by providing incentives to would-be investors. These incentives include tax breaks, seed money, concessional pricing for land, subsidies for utilities and patent costs, and the promise of a single-window clearance on regulatory matters involving the state.6
India's plans for promoting its biopharmaceutical and other biotech sectors are fairly ambitious and may be more difficult to realize as swiftly as the country's planners would like. As with many government initiatives around the globe, the DBT's budget (approaching $200 million in 2008) would seem to be spread thinly if it is to accommodate the long list of priority projects the organization intends to support.9
Still, India clearly is intent on improving itself in the biotech sector, and the desire to make Indian biotech as good as Indian IT seems to be widespread. It is, therefore, likely that in another decade, India will at least have one of Asia's best biotech capabilities.
1. Biocon looks to Rs 650-cr SEZ for tax relief. The Hindu Business Line. 2005 Oct 20. Available from: www.thehindubusiness-line.com/2005/10/20/stories/2005102001630200.htm
2. The Patents Amendment Act, 2005. Available from: www.patentoffice.nic.in/ipr/patent/patent_2005.pdf
3. Yarnell A. Keeping postdocs at home in India. Chem Eng News 84. 2006 Mar 20. Available from: www.pubs.acs.org/cen/coverstory/84/8412India3.html
4. Department of Biotechnology. National Biotechnology Development Strategy. 2007 Nov. Available from: www.dbtindia.nic.in/biotechstrategy/National%20Biotechnology%20Development%20Strategy.pdf
5. Department of Plant and Molecular Biology, University of Delhi. India's national biotechnology regulatory authority functional in two years. Available from: www.south.du.ac.in/pmb/mod.php?mod=publisher&op=viewarticle&artid=55
6. Kumar A. Biogeneric manufacturing in India. In: Langer E, editor. Advances in biopharmaceutical technology in India. Gaithersburgh, MD: Bioplan; 2008 Feb.
7. Singh S. India doles out pharma incentives. Red Herring. 2007 Feb 27. Available from: www.redherring.com/Home/21468
8. India Brand Equity Foundation/Ernst & Young. Biotechnology. Available from: www.tamilnadunri.com/Indian%20Market/26.%20Bio-technology.pdf
9. Clearstate Pte. Ltd. Biotech: India's new global pitch. 2007 Jul 23. Available from: www.clearstate.com/admin/data/Clearstate_India_Biotech.pdf
Eric S. Langer is president and managing partner at BioPlan Associates, Inc., Rockville, MD. He is also the editor of Advances in Biopharmaceutical Technology in India, 301.921.9074, firstname.lastname@example.org